CPI RSV F vaccine - Blue Lake Biotechnology
Alternative Names: BL-200 RSV; BLB-201; CPI-RSV-F Vaccine - Blue Lake Biotechnology; Intranasal RSV vaccine - Blue Lake Biotechnology; PIV5-vectored RSV vaccine - Blue Lake BiotechnologyLatest Information Update: 25 Mar 2024
At a glance
- Originator Blue Lake Biotechnology
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
Most Recent Events
- 21 Mar 2024 Interim immunogenicity and adverse events data from a phase-I/II trial in Respiratory syncytial virus infections released by Blue Lake Biotechnology
- 25 Oct 2023 Adverse events and immunogenicity data from a phase-I trial in Respiratory syncytial virus infections released by Blue Lake Biotechnology (Intranasal)
- 29 Mar 2023 Phase-I/II clinical trials in Respiratory syncytial virus infections (Prevention, In infants, In children) in USA (Intranasal) (NCT05655182)